CAG
DNA icon

Crestwood Advisors Group’s Ginkgo Bioworks DNA Stock Holding History

Crestwood Advisors Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-924
Closed -$12.4K – 445
2024
Q2 		$12.4K Hold
924
– – ﹤0.01% 424
2024
Q1 		$42.9K Hold
924
– – ﹤0.01% 414
2023
Q4 		$62.5K Hold
924
– – ﹤0.01% 401
2023
Q3 		$66.9K Buy
924
+500
+118% +$40K ﹤0.01% 358
2023
Q2 		$31.6K Sell
424
-38
-8% -$2.25K ﹤0.01% 254
2023
Q1 		$24.6K Hold
462
– – ﹤0.01% 258
2022
Q4 		$31.2K Hold
462
– – ﹤0.01% 260
2022
Q3 		$58K Hold
462
– – ﹤0.01% 259
2022
Q2 		$44K Hold
462
– – ﹤0.01% 261
2022
Q1 		$74K Buy
+462
New +$89.9K ﹤0.01% 280

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Crestwood Advisors Group's DNA Position: Q3 2024 in Review

Crestwood Advisors Group sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 924 shares — an estimated $12.4K sold.

Crestwood Advisors Group first reported a position in DNA in Q1 2022 and held it in 10 quarters. The position peaked at $74K in Q1 2022. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Crestwood Advisors Group reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Crestwood Advisors Group sold 924 Ginkgo Bioworks shares in Q3 2024, an estimated $12.4K.
  • Crestwood Advisors Group first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 10 quarters.
  • Crestwood Advisors Group's Ginkgo Bioworks position peaked at $74K in Q1 2022.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Crestwood Advisors Group's 13F filing for Q3 2024, filed 30 Oct 2024.